Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02916979
Other study ID # D16127
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 6, 2016
Est. completion date February 11, 2022

Study information

Verified date October 2023
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant. A pilot clinical trial to characterize the incidence, prevalence and function of myeloid-derived suppressor cells (MDSCs) and immune checkpoint regulators (V-domain Ig Suppressor of T-cell Activation [VISTA], cytotoxic T-lymphocyte- associated protein 4 [CTLA-4], programmed death-ligand 1 [PD-L1]) during early immune recovery following an allogeneic stem cell transplant. The site will use a myeloablative regimen of fludarabine with busulfan, adopted from CALGB 100801, to define clinical endpoints, including engraftment, 100 day survival and one year survival (Objective #1). The site will characterize the incidence, prevalence and function of MDSCs and immune checkpoint regulators in patients' blood and bone marrow following transplantation (Objective #2). The site will correlate these laboratory results with clinical outcomes and the incidence of graft-versus-host disease (GVHD). As an exploratory aim, in those patients experiencing GVHD and requiring treatment, the site will define the MDSCs frequency and checkpoint regulator expression and correlate these results with the patient's response to GVHD therapy.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 11, 2022
Est. primary completion date June 7, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age less than or equal to 75 years 2. The patient must be approved for transplant by the treating transplant physician. This includes completion of their pretransplant workup, as directed by standard Dartmouth-Hitchcock Medical Center (DHMC) Standard Operating Procedures (SOPs). DHMC SOP for Pretransplant Evaluation of allogeneic recipient. 3. The patient must have a disease, listed below, with treatment responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include: 1. Acute leukemia AML (Acute Myeloid Leukemia), ALL (Acute Lymphoid Leukemia) 2. Chronic leukemia CML (Chronic Myeloid Leukemia), CLL (Chronic Lymphoid Leukemia) 3. Myelodysplasia 4. Myelofibrosis 5. Lymphoma NHL (Non-Hodgkin's Lymphoma) and Hodgkin's disease 6. Plasma cell disorder, including myeloma, Waldenstrom's Macroglobulinemia 4. Donor availability- the patient must have an identified donor 1. Sibling Availability of a 6 out of 6 identical donor 2. Unrelated donor: Availability of a 6 out of 6 unrelated donor 5. No human immunodeficiency virus (HIV) infection or active hepatitis B or C 6. Easter Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 7. Diffusing capacity of the lungs for carbon monoxide DLCO more than or equal to 40 percent predicted 8. Left ventricular ejection fraction more than or equal to 35 percent 9. Serum bilirubin less than 2x upper limit of normal transaminases less than 3x normal at the time of transplant 10. No active or uncontrollable infection 11. In female, a negative pregnancy test if experiencing menstrual periods 12. No major organ dysfunction precluding transplantation 13. No evidence of an active malignancy that would limit the patient's survival to less than 2 years. If there is any question, the principal investigator can make a decision. Exclusion Criteria: 1. Psychiatric disorder or a mental deficiency of the patient that is sufficiently severe to make compliance with the treatment unlikely, and making informed consent impossible. 2. Major anticipated illness or organ failure incompatible with survival from bone marrow transplant. 3. History of refractory systemic infection Donor eligibility 1. Human leukocyte antigen (HLA) 6 out of 6 matched related or unrelated donor. 2. The donor must be healthy and must be willing to serve as a donor, based on standard guidelines 3. The donor must have no significant comorbidities that would put the donor at marked increased risk 4. There is no age restriction for the donor 5. Informed consent must be signed by donor, if sibling donor, or by third party if unrelated donor. Donor Exclusion Criteria 6. The National Marrow Donor Program (NMDP) guidelines for exclusion criteria will be used. In addition, the following donors are NOT eligible: 7. Syngeneic donor 8. Pregnant or lactating donor 9. Human immunodeficiency virus (HIV) or active HepB or C in the donor 10. Donor unfit to receive Granulocyte-colony stimulating factor (GCSF) and undergo apheresis 11. A donor with a psychiatric disorder or mental deficiency that makes compliance with the procedure unlikely and informed consent impossible

Study Design


Intervention

Drug:
Fludarabine
Fludarabine: 30 mg/m2 daily for 5 days
Busulfan
Busulfan: 100 mg/m2 daily for 4 days
Biological:
Rabbit ATG
Rabbit ATG: Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4
Drug:
Methotrexate
Methotrexate: Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11

Locations

Country Name City State
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients who are surviving at 100-Days post-transplant 100-Day survival of patients 100 Days
Secondary Time to marrow engraftment Time to marrow engraftment (defined as absolute neutrophil count > 500/mm3 and platelets > 20,000/mcl for three consecutive days (count first day as engraftment) 100 Days
Secondary Assessing all subjects' response to treatment at 100 days post-transplant Response to treatment at 100 days using standard international response criteria, based on CIBMTR definitions. 100 Days
Secondary Assessing all subjects' response to treatment at 1 year post-transplant Response to treatment at one year using standard international response criteria, based on CIBMTR definitions. 365 Days
Secondary Assessing all subjects' survival at 1 year post-transplant One year survival 365 Days
Secondary Assessing the mortality rate of patients in the first 100 days post-transplant Treatment-related mortality in the first 100 days 100 Days
Secondary Assessing the number of treatment-related adverse events Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 365 Days
Secondary Collecting the incidents of GvHD experienced by patients post-transplant Incidence of acute and chronic GVHD 365 Days
Secondary Assessing the donor-chimerism at 30, 60 and 90 days post-transplant Donor-recipient chimerism following transplant at Days 30, 60 and 90. 30, 60, and 90 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
Recruiting NCT04111809 - Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care